2790. Phase 1 study of no-carrier added (NCA) 177Lu-DOTATATE (SNU-KB-01) in patients with somatostatin receptor-positive neuroendocrine tumors: the first clinical trial of peptide receptor radionuclide therapy (PRRT) in Korea
Ryoo HG, Suh MS, Kang KW, Lee DW, Han SW, Cheon GJ
Cancer Res Treat 2022 Apr 22. doi: 10.4143/crt.2021.1022. Online ahead of print.Link
2789. Gut bacteria-derived 3-phenylpropionylglycine mitigates adipocyte differentiation of 3T3-L1 cells by inhibiting adiponectin-PPAR pathway
Hae Rim Jung, Yumi Oh, Dongjun Jang, Seungjae Shin, Soo-Jin Lee, Jiwon Kim, Sang Eun Lee, Jaeik Oh, Giyong Jang, Obin Kwon, Yeonmi Lee, Hui-Young Lee, Sung-Yup Cho
2787. Augmentation of the RNA m6A reader signature is associated with poor survival by enhancing cell proliferation and EMT across cancer type
Jaeik Oh, Chanwoong Hwa, Dongjun Jang, Seungjae Shin, Soo-Jin Lee, Jiwon Kim, Sang Eun Lee, Hae Rim Jung, Yumi Oh, Giyong Jang, Obin Kwon, Joon-Yong An, Sung-Yup Cho
2783. Clinicopathologic and Genetic Features of Primary T-cell Lymphomas of the Central Nervous System: An Analysis of 11 Cases Using Targeted Gene Sequencing
Jeemin Yim 1, Jiwon Koh 1 2, Sehui Kim 1 3, Seung Geun Song 1, Jeong Mo Bae 1 2, Hongseok Yun 2, Ji-Youn Sung 4, Tae Min Kim 5 6, Sung-Hye Park 1, Yoon Kyung Jeon 1 6